// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
A
Inclisiran (GalNAc-siRNA against PCSK9) achieves sustained LDL-C lowering with twice-yearly dosing
ORION-9/10/11 phase 3 trials; ~50% LDL-C reduction.
Module 10 · Beyond CRISPR: ASO, siRNA, mRNA, AAV, and Cell Therapy →A
Patisiran improves polyneuropathy and quality-of-life outcomes in hereditary ATTR amyloidosis
APOLLO trial, NEJM 2018.
Module 10 · Beyond CRISPR: ASO, siRNA, mRNA, AAV, and Cell Therapy →A
Onasemnogene abeparvovec (Zolgensma) preserves motor function in pre-symptomatic SMA when given before 6 weeks
SPR1NT trial; treatment timing is decisive.
Module 10 · Beyond CRISPR: ASO, siRNA, mRNA, AAV, and Cell Therapy →